Potential 10 Bagger For a pharma/cbd play they have low shares outstanding and this will run fast once they sell their HMGB1 patent for several million. Chart has been destroyed since cannabis stocks took a huge hit. Once we get an update on their Phase 2B results we could see a nice bounce. Trials supposed to be done in a few weeks & already speculated to be in talks to sell their drug patent outiright.
Reformation (formerly 180 Pharmaceuticals) has had a patent to start developing the drug since 2011. The drug being developed targets 5 major diseases: Osteoarthritis, Myocardial Infarction, Type 1 Diabeties, Parkinson's Disease & Liver Disease.
"ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. Through the combination of this molecule and synthetic non-psychoactive cannabinoids they are developing a first-in-class therapy. ReFormation Pharmaceuticals is led by world-class scientist, Founder, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford."
I think many will be surprised. Don't sleep on them & do your DD. GLTA.